AR062886A1 - Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento - Google Patents
Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamentoInfo
- Publication number
- AR062886A1 AR062886A1 ARP070104125A ARP070104125A AR062886A1 AR 062886 A1 AR062886 A1 AR 062886A1 AR P070104125 A ARP070104125 A AR P070104125A AR P070104125 A ARP070104125 A AR P070104125A AR 062886 A1 AR062886 A1 AR 062886A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- pharmaceutical composition
- pirazolopirimidine
- tiazol
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- -1 Thiazole pyrazolopyrimidine compound Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 108091005471 CRHR1 Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82626406P | 2006-09-20 | 2006-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062886A1 true AR062886A1 (es) | 2008-12-10 |
Family
ID=38924802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104125A AR062886A1 (es) | 2006-09-20 | 2007-09-18 | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8030304B2 (OSRAM) |
| EP (1) | EP2094709B1 (OSRAM) |
| JP (1) | JP5161226B2 (OSRAM) |
| KR (1) | KR101088239B1 (OSRAM) |
| CN (1) | CN101516887B (OSRAM) |
| AR (1) | AR062886A1 (OSRAM) |
| AT (1) | ATE481405T1 (OSRAM) |
| AU (1) | AU2007297421B2 (OSRAM) |
| BR (1) | BRPI0717023B8 (OSRAM) |
| CA (1) | CA2663511C (OSRAM) |
| CL (1) | CL2007002693A1 (OSRAM) |
| CR (1) | CR10682A (OSRAM) |
| CY (1) | CY1110854T1 (OSRAM) |
| DE (1) | DE602007009305D1 (OSRAM) |
| DK (1) | DK2094709T3 (OSRAM) |
| EA (1) | EA015179B1 (OSRAM) |
| ES (1) | ES2350282T3 (OSRAM) |
| HR (1) | HRP20100516T1 (OSRAM) |
| IL (1) | IL197614A (OSRAM) |
| MA (1) | MA30798B1 (OSRAM) |
| MX (1) | MX2009003125A (OSRAM) |
| MY (1) | MY146388A (OSRAM) |
| NO (1) | NO20091489L (OSRAM) |
| NZ (1) | NZ575572A (OSRAM) |
| PE (1) | PE20081377A1 (OSRAM) |
| PL (1) | PL2094709T3 (OSRAM) |
| PT (1) | PT2094709E (OSRAM) |
| RS (1) | RS51545B (OSRAM) |
| SI (1) | SI2094709T1 (OSRAM) |
| TN (1) | TN2009000095A1 (OSRAM) |
| TW (1) | TWI402269B (OSRAM) |
| UA (1) | UA96458C2 (OSRAM) |
| WO (1) | WO2008036579A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AR073708A1 (es) * | 2008-10-02 | 2010-11-24 | Lilly Co Eli | Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| IL296683B2 (en) * | 2014-01-21 | 2023-12-01 | Neurocrine Biosciences Inc | Preparations for the treatment of congenital adrenal hyperplasia |
| PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| KR102571296B1 (ko) | 2016-09-07 | 2023-08-28 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | P-tau를 감소시키고 인지를 개선하는 알로스테릭 코르티코트로핀-방출 인자 수용체 1 (crfr1) 길항제 |
| WO2019036503A1 (en) * | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| EP3630763A4 (en) * | 2017-08-14 | 2021-03-10 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| CN112423747A (zh) * | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| CN109134481B (zh) * | 2018-08-07 | 2021-05-14 | 中山大学 | 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用 |
| TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| CN120284862A (zh) | 2018-12-07 | 2025-07-11 | 纽罗克里生物科学有限公司 | 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式 |
| WO2021016208A1 (en) * | 2019-07-19 | 2021-01-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| TW202134241A (zh) * | 2019-12-04 | 2021-09-16 | 美商紐羅克里生物科學有限公司 | Ｃｒｆ受體拮抗劑及使用方法 |
| GR1010096B (el) * | 2020-07-02 | 2021-10-08 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης |
| CN116322544B (zh) * | 2020-08-12 | 2024-08-02 | 云杉生物科学公司 | 用于治疗多囊卵巢综合征的方法和组合物 |
| EP4203964A1 (en) | 2020-08-26 | 2023-07-05 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| CA3211644A1 (en) | 2021-03-19 | 2022-09-22 | Christine FERRARA-COOK | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
| JP2024539907A (ja) * | 2021-11-19 | 2024-10-31 | スプルース バイオサイエンシーズ，インク． | チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2023163945A1 (en) * | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ286892B6 (en) | 1992-12-17 | 2000-07-12 | Pfizer | Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon |
| CZ244598A3 (cs) * | 1996-02-07 | 1998-10-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidiny jako antagonisty CRF receptoru |
| ATE375344T1 (de) | 1996-07-24 | 2007-10-15 | Bristol Myers Squibb Pharma Co | Azolotriazine und pyrimidine |
| NZ333777A (en) * | 1996-07-24 | 2000-07-28 | Du Pont Pharm Co | (1,5-a) pyrazolo and triazole triazines and pyrimidines |
| CZ68199A3 (cs) | 1996-08-28 | 1999-11-17 | Pfizer Inc. | 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob |
| EP1040831A3 (en) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU4203500A (en) * | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| PL354982A1 (en) * | 1999-09-30 | 2004-03-22 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| IL157615A0 (en) * | 2001-03-13 | 2004-03-28 | Bristol Myers Squibb Co | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| MY143499A (en) * | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
-
2007
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 EP EP07842582A patent/EP2094709B1/en active Active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/sr unknown
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en not_active Ceased
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
-
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
-
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062886A1 (es) | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| EA200971143A1 (ru) | Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения | |
| BRPI0718714B8 (pt) | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende | |
| HRP20090235A2 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub> | |
| PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
| AR074632A1 (es) | Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer | |
| UY30183A1 (es) | Derivados de quinolina | |
| NZ595759A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| DE602006009773D1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| PE20091042A1 (es) | Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841 | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| GEP20156351B (en) | Glucagon receptor modulator | |
| BRPI0821266B8 (pt) | Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica | |
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| MX2009008323A (es) | Derivados heterociclicos como receptores muscarinicos m3. | |
| JP2015502371A5 (OSRAM) | ||
| AU2006294633A8 (en) | 7-[2-[4- (6-fluoro-3-methyl -1,2-benzisoxazol-5-yl) -1-piperazinyl]ethyl] -2- ( 1-propynyl) -7h-pyrazolo- [ 4,3-e]-[1,2,4] -triazolo- [1,5-c] -pyrimidin- 5 amine | |
| TW200531694A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration |